Table 1 Characteristics of the included studies in systematic review (N = 19)
First author, year, and country | Study | Disease | No. (MSCs+/MSCs−) | Median/mean age (year) (MSCs+/MSCs−) | HSCs source (donor type) | HSCs HLA matching | MSCs source (donor type) | MSCs dose (106/kg) | Median follow-up time (month) (MSCs+/MSCs−) |
|---|---|---|---|---|---|---|---|---|---|
Ning, 2008, China [24] | RCT | HM | 25 (10/15) | 38/37 | BM, PB, BM+PB (RD) | ID | BM (RD) | 0.34 (0.03–1.53) | 36.6 (0.6–44.0) |
Ghavamzad, 2010, Iran [27] | RCT | NMD | 48 (25/23) | 17/16 | PB, BM (RD) | ID | NA (RD) | 1.45–1.80 | 10 (1–28) |
Liu, 2011, China [22] | RCT | HM | 55 (27/28) | 30/31.5 | BM+PB (RD) | HID | BM (RD, TPD) | 0.3–0.5 | 23.7 (0.7–33.5) |
Wu, 2013b, China [28] | RCT | HM | 20 (8/12) | 9.8/8.5 | UCB (URD) | MM | UCB (URD) | 7.19 (2.44–10.12) | 16.5 (11–27)/18.5 (12–31) |
Mareika, 2016, Belarus [29] | RCT | HM | 22 (10/12) | 13 (5–24) | NA (NA) | NA | BM (NA) | 1.56 ± 0.4 | 38 (5.7–59.4) |
Xiang, 2017, China [13] | RCT | HM | 64 (32/32) | 5.5 ± 1.4/5.2 ± 1.2 | PB (URD) | ID | UCB (URD) | 1.0 | 24 |
Ball, 2007, Netherlands [16] | HCT | HM and NMD | 61 (14/47) | 8 (1–16)/7.1 (1–17) | PB (RD) | HID | BM (RD) | 1.6 (1.0–3.3) | (3–28)/(32–110) |
Gonzalo-Daganzo, 2009, Spain [30] | PCT | HM | 55 (9/46) | 32/35 | UCB (URD) | MM | BM (URD) | 1.2 (1.04–2.22) | 7.4 (1–22)/24 (1–107) |
MacMillan, 2009, USA [31] | HCT | HM | 30 (7/23) | 7.5 (0.2–16) | UCB (URD) | MM | BM (RD) | 2.1 (0.9–5.0) | 81.6 |
Baron, 2010, Belgium [32] | HCT | HM | 36 (20/16) | 58/55 | PB (URD) | MM | BM (URD) | NA | 18.7 (13.3–30.3) |
Hou, 2010 China [33] | PCT | HM | 35 (15/20) | 32 (14–45)/28.5 (12–48) | NA (RD) | HID | BM (RD, 2; TPD, 13) | 0.41 (0.22–0.52) | 6 |
Bernardo, 2011, Italy [15] | HCT | HM | 52 (13/39) | 2/4 | UCB (URD) | MM | BM (RD) | 1.9 (1–3.9) | 36 (28/42) |
Lee, 2013, Korea [14] | HCT | HM | 16 (7/9) | 6.9/9.5 | UCB (URD) | MM | UCB (URD) | 1.0 in 4 pts, 5.0 in 3 pts | 24 |
Wu, 2013a, China [34] | PCT | HM and NMD | 14 (5/9) | 8.8/7.8 | UCB (URD) | MM | UCB (URD) | 5.76 (3.12–8.21) | 27 (24–31) |
Xiao, 2013, China [35] | PCT | HM and NMD | 15 (7/8) | 30 (12–60)/35.5 (16–54) | PB (URD) | NA | UCB (URD) | NA | 15 |
Wang, 2015, China [36] | PCT | NMD | 14 (7/7) | 28 (22–43) | PB (RD) | MM | UCB (URD) | Total, 30.0 | 14.5 (6–74) |
Zhang, 2015, China [37] | HCT | HM | 49 (22/27) | 22.5 (3–48)/23 (3–43) | PB (URD) | MM | UCB (URD) | 1.0 | 22 (1–98) |
Kang, 2017, China [38] | HCT | HM | 47 (34/13) | 7 (1.5–13) | PB, BM (RD) | HID | UCB (URD) | 1.0 | 20 (0.5–67) |
Ghavamzad, 2017, Iran [39] | PCT | NMD | 70 (41/29) | NA | NA (RD) | ID | NA (URD) | 1.0–2.0 | 35.76/31.44 |